Use of Dynamic Contrast‐Enhanced Magnetic Resonance Imaging Combined With Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19‐9 in Predicting Colorectal Cancer Liver Metastasis

• Published in: Journal of clinical ultrasound Vol. 53; no. 4; pp. 612 - 619
• Main Authors: Ji, Hong‐Bo, Qian, Bo, Hu, Jian‐Jun, Qi, Wei, Che, Zi‐Gang
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.05.2025; Wiley Subscription Services, Inc
• Subjects: Adult; Aged; Antigens; Biomarkers, Tumor - blood; CA-19-9 Antigen - blood; Cancer; carbohydrate antigen 19‐9; Carbohydrates; Carcinoembryonic antigen; Carcinoembryonic Antigen - blood; Chi-square test; Colorectal cancer; colorectal cancer liver metastases; Colorectal carcinoma; Colorectal Neoplasms - blood; Colorectal Neoplasms - pathology; Contrast agents; Contrast Media; dynamic contrast‐enhanced magnetic resonance imaging; Effectiveness; Female; Humans; Image Enhancement - methods; Liver; Liver - diagnostic imaging; Liver cancer; Liver Neoplasms - blood; Liver Neoplasms - diagnostic imaging; Liver Neoplasms - secondary; Magnetic resonance imaging; Magnetic Resonance Imaging - methods; Male; Medical imaging; Metastases; Metastasis; Middle Aged; Patients; Predictive Value of Tests; Retrospective Studies; Statistical analysis; carbohydrate antigen 19‐9; carcinoembryonic antigen; colorectal cancer liver metastases; dynamic contrast‐enhanced magnetic resonance imaging
• ISSN: 0091-2751; 1097-0096; 1097-0096
• DOI: 10.1002/jcu.23917

ABSTRACT Background Dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI) combined with serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19‐9 (CA19‐9) levels to evaluate the efficacy of colorectal cancer liver metastasis (CRCLM) treatment is still rare. Purpose To investigate the predictive value of DCE‐MRI combined with serum CEA and CA 19‐9 concerning the efficacy of comprehensive treatment for CRCLM. Materials and Methods A total of 120 patients with CRC were retrospectively recruited using convenience sampling between May 2019 and March 2024. After treatment, they were divided into two groups according to the treatment efficacy: responders (86 cases) and non‐responders (34 cases), and their clinical data were collected for comparison. Results Before treatment, there were statistically significant differences between the groups in terms of the proportion of positive CEA (χ2 = 17.364, p < 0.001), the proportion of positive CA 19‐9 (χ2 = 23.639, p < 0.001), the rate constant of a contrast agent from the vascular to the interstitial compartment (Ktrans) (χ2 = 2.341, p = 0.023), and the rate constant between the extravascular extracellular space (EES) (Kep) (χ2 = 2.556, p = 0.011). The values of Ktrans, Kep, CEA, and CA 19‐9 reflected a certain degree of predictive value for the efficacy of comprehensive treatment in patients with CRCLM (p < 0.05). The combination of the four measurements is better than any single value, with an area under the curve of 0.898 (95% CI: 0.833, 0.922). Conclusion Dynamic contrast‐enhanced magnetic resonance imaging, CEA, and CA 19‐9 have predictive value for the early efficacy of comprehensive treatment for CRCLM. The study subjects were mainly CRC patients (n = 120), all of whom underwent the same comprehensive treatment regimen and were divided into the effective treatment group (n = 86) and the ineffective treatment group (n = 34) according to efficacy after treatment. Basic clinical information was collected from the patients, measured using DCE‐MRI, and serum CEA and CA19‐9 information was collected. The results showed that dynamic contrast‐enhanced MRI, CEA, and CA 19‐9 had predictive value for the early efficacy of CRCLM combined therapy.